Alaa El Gendy, MD
Pulmonary Disease · Lehigh Acres, FLNPI 1437186970
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (45.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Intuitive Surgical at 52.2% of the total. Reporting peaked in 2024 at $6,659 and has fallen 98.1% since, to $125 in 2025.
Across 167 payments — averaging $72.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- Olympus Corporation Of The Americas$2K
- GSK$1K
- AstraZeneca$797
- Grifols USA, LLC$371
- Boehringer Ingelheim$206
- plus $1K from 18 others
Across 21 payments — averaging $32,952 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Philips North America LLC$688K
- Boehringer Ingelheim$4K
What the payments were for
- Travel & lodging$2,75023%
- Food & beverage$3,81931%
- Education$5,50945%
- Gifts$610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 8 | $6,331 |
| Olympus Corporation Of The Americas | 20 | $1,988 |
| GSK | 57 | $1,275 |
| AstraZeneca | 25 | $797 |
| Grifols USA, LLC | 16 | $371 |
| Boehringer Ingelheim | 10 | $206 |
| Inspire Medical Systems, Inc. | 2 | $159 |
| Sanofi | 4 | $150 |
| Johnson & Johnson | 2 | $150 |
| Lilly USA, LLC | 1 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $88 |
| Shire North American Group Inc | 4 | $85 |
| Pulmonx Corporation | 1 | $75 |
| Medical Graphics Corporation | 1 | $61 |
| Mylan Specialty L.p. | 3 | $59 |
| Olympus America Inc. | 1 | $45 |
| Genentech USA, Inc. | 2 | $41 |
| Mallinckrodt Enterprises LLC | 1 | $25 |
| Novartis | 1 | $24 |
| Circassia Inc. | 1 | $19 |
| Electromed, Inc. | 1 | $18 |
| Optinose US, Inc. | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Harmony Biosciences LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$6,289
- Olympus Respiratory Accessories$1,655
- Olympus Capital Accessories$1,655
- Olympus EBUS Bronchoscopes$987
- Olympus Bronchoscopes$668
- Inspire$144
- ANORO$137
- TAGRISSO$125
- ZEPBOUND$125
- NUCALA$119
- IMFINZI$112
How this compares
$12,139 in reported general payments places this provider in the 75th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Spiriva RespimatTiotropium Bromide | 19 | $17,785 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $15,567 |
| DuleraMometasone/Formoterol | 12 | $4,386 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 50 | $1,208 |
| Montelukast Sodium | 15 | $387 |
| Fluticasone Propionate | 18 | $235 |
| Fluconazole | 14 | $116 |
| Omeprazole | 15 | $72 |
| Azithromycin | 15 | $25 |
| Prednisone | 14 | $21 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSpiriva Respimat | $206 | $17,78519 claims |
| GSKTrelegy Ellipta | $1,275 | $15,56714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Lehigh Acres
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Jose Soto SotoJacksonville$504K
- Javier Perez FernandezMiami$496K
- Domenick ReinaTampa$469K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.